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tamoxifen from a German health service perspective. METHODS: A semi-Markov 
model was adapted to include the 100-month clinical trial efﬁcacy data. Kaplan-Meier 
curves on time to recurrence (TTR) from the ATAC trial were ﬁtted by survival regres-
sion including a treatment coefﬁcient. Treatment speciﬁc progression rates were 
extrapolated to 10 years, and were assumed equivalent based on pooled treatment 
arms thereafter. Survival probabilities after recurrence were identical for all treat-
ments, based on German national mortality data. Published literature and physician 
survey provided data on resource use and unit costs and utilities. Probabilistic analysis 
was carried out to obtain incremental cost-effectiveness ratios and cost-effectiveness 
acceptability curves. Sensitivity analyses were conducted. RESULTS: Over 25 years 
anastrozole patients gained 0.32 QALYs at a cost of a6,819 per patient, resulting in 
an ICER of a21,069 (95%CI: a12,567–a46,604) per QALY gained, vs tamoxifen. 
With a 90% probability the ICER was below a30,000/QALY. The results were 
robust to plausible changes in parameters tested in sensitivity analyses, including the 
hazard ratio for TTR. CONCLUSIONS: This is the ﬁrst cost-utility analysis of an 
aromatase inhibitor based on extended follow-up data. Anastrozole’s carryover 
treatment effect beyond therapy completion at 5 years translates into favourable 
cost-effectiveness results against tamoxifen for PM HR EBC women from a German 
national health insurance perspective.
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OBJECTIVES: To evaluate cost-utility of docetaxel (75 mg/m2 every 3 weeks) com-
pared with best supportive care (BSC) or pemetrexed (500 mg/m2 every 3 weeks) as 
second-line therapy in advanced non-small cell lung cancer in the Polish setting. 
METHODS: A cost-utility approach was adopted, evaluating total direct costs 
incurred by the Polish National Health Fund (NHF), life years gained (LYG) and 
quality-adjusted life years (QALY). A micro-simulation Markov model was used to 
estimate utilities and costs of treatment. The ﬁrst course of chemotherapy was assumed 
as the starting-time point of the model. Simulation was terminated at the time of the 
patient’s death or after two years following start of the treatment. It was assumed that 
patients would undergo 4 cycles of chemotherapy or less if progression occurred 
during treatment. In case of progression of disease chemotherapy would be terminated 
and patients would receive palliative care until death. Transition probabilities between 
health states were calculated based on a systematic review of RCTs. Health states 
utilities were taken from published literature. Costs were taken from NHF catalogue. 
Probabilistic sensitivity analysis was performed in order to estimate the probability 
that docetaxel was cost effective in Polish settings where threshold is about 91,000 
polish zloty (PLN). RESULTS: Incremental costs for docetaxel compared with BSC 
was PLN57,498 per LYG and PLN105,956 per QALY. In 2-years time horizon 
docetaxel was PLN13,582 less costly than pemetrexed (CI95%: 8,224; 17,704). The 
probability of docetaxel cost effectiveness over BSC was 99.71% for LYG and 10.11% 
for QALY. The probability of docetaxel cost effectiveness over pemetrexed was 
99.78% for LYG and 100% for QALY. CONCLUSIONS: Docetaxel seems to be cost 
effective in comparison with BSC and pemetrexed in the Polish setting.
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OBJECTIVES: More than one million new cases of colorectal cancer are diagnosed 
worldwide annually. In Ireland, incidence rates are among the highest in western 
Europe, survival is lower than the European average, and mortality in men exceeds 
that in other western European countries. We evaluated the cost-effectiveness of a 
population-based colorectal cancer screening programme in Ireland. METHODS: 
Three screening scenarios were assessed: 1) biennial guaiac-based faecal occult blood 
testing (gFOBT) in those aged 55–74; 2) biennial faecal immunochemical testing (FIT) 
in those aged 55–74; and 3) once-only ﬂexible sigmoidoscopy (FSIG) at age 60. A 
Markov model was used to followed a cohort of 55-year-old individuals over their 
lifetime. Model parameters were obtained from local data, literature review and expert 
clinical opinion. Costs included screening and diagnostic tests, cancer treatment, 
complications, and surveillance of screen-detected adenomas. Health outcomes were 
assessed in quality-adjusted life years (QALYs). Costs and outcomes were discounted 
at 4% per annum. Screening scenarios were compared with the status quo (“no screen-
ing”). Probabilistic sensitivity analyses were undertaken. RESULTS: All three screen-
ing scenarios were highly cost-effective compared to no screening. In the base-case 
analysis, FSIG had the lowest incremental cost-effectiveness ratio (ICER  a589 per 
QALY gained), followed by FIT (a1,696 per QALY gained), and gFOBT (a4428 per 
QALY gained). gFOBT was dominated. Compared to FSIG, FIT was associated with 
a greater health gain, and greater lifetime reductions in colorectal cancer incidence 
(15%) and mortality (36%). However, it was more costly than FSIG, required more 
colonoscopies, and would result in more complications. The ICER for FIT versus FSIG 
was a2058 per QALY gained. Results were robust to variations in parameter esti-
mates. CONCLUSIONS: These results suggest that population-based colorectal cancer 
screening would be a highly cost-effective in Ireland. FIT is the optimal screening 
strategy since it as associated with the greatest health gain.
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OBJECTIVES: Prostatic cancer is the second most frequent cancer and the third 
highest cause of cancer-related deaths in Italy. Age is the principal risk factor and 
given the ageing Italian population, it seems that the related health care expenditure 
is bound to increase, causing the need for pharmacoeconomic evaluation of therapies 
available. METHODS: We performed a cost/utility analysis using a Markov model of 
hormonal therapies in patients with advanced prostate cancer who underwent radical 
prostatectomy, from biochemical recurrence to death. Nine androgen suppression 
therapies were considered: orchiectomy, two nonsteroidal antiandrogens (NSAA), four 
luteinising hormone-releasing hormone (LHRH) agonists, cyproterone acetate and the 
maximal androgen blockade (MAB) obtained with the association of a NSAA and a 
LHRH. In the simulation, the androgen suppression therapies were started at PSA 
recurrence and continued until death. The model used the Italian NHS prospective 
and a patient’s lifetime simulation horizon. Drug costs were calculated for each 
therapy, considering the less costly brand. RESULTS: All therapies produced a life 
expectancy (LE) of about 12 life years (LYs) with a small variability ranging from 
12.3 LYs for MAB to 11.37 LYs for NSAA-ﬂutamide. Quality adjusted life expectancy 
ranged from 9.98 QALYs for MAB to 9.28 QALYs for NSAA-ﬂutamide. The cost per 
patient presented more variability, from a12,538 for orchiectomy to a59,496 for 
NSAA-bicalutamide. Orchiectomy provided the most cost/effective alternative with 
a1300/QALY. In the LHRH-agonists class leuprorelin was the most cost/effective at 
about a2200/QALY. CONCLUSIONS: MAB was identiﬁed as the most effective and 
the most costly therapy. Orchiectomy was less effective but involved the lowest cost 
and, thus, represented the most cost/effective strategy. Nonetheless, its application in 
actual clinical practice is difﬁcult and it is almost always refused by patients. Among 
the class of LHRH-agonists, leuprorelin (22.5 mg–7.5 mg) dominated the alternatives 
and provided an excellent therapeutic strategy.
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OBJECTIVES: At a median follow-up of 100 months in the ATAC trial, anastrozole 
demonstrated signiﬁcant improvements compared with tamoxifen in disease-free sur-
vival (HR: 0.85, p  0.003) and time-to recurrence (TTR) (HR: 0.76, p  0.0001). 
Absolute difference in TTR increased over time, 2.8% at 5 years and 4.8% at 9 years. 
Recurrence rates remained signiﬁcantly lower on anastrozole after treatment comple-
tion. This study assesses the long-term cost-effectiveness of adjuvant treatment 
with anastrozole versus tamoxifen in women with early breast cancer in Sweden. 
METHODS: A Markov model was developed to integrate trial data with external 
data on costs and quality of life speciﬁc for Swedish breast cancer patients. The model 
adopts a life-long perspective and the primary outcome measure was QALYs. In the 
base-case model, TTR for tamoxifen and anastrozole diverge out to 10 years. Mortal-
ity risks for recurred and non-recurred patients are based upon trial data and national 
statistics. Resource utilization and utility estimates were based on Swedish data for 
patients in different stages of breast cancer. Utility weights were estimated with EQ-
5D. All costs and beneﬁts were discounted at 3% at 2005-year prices. RESULTS: 
In base-case, patients treated with anastrozole had a higher lifetime expected mean 
cost of SEK 16,000 compared to patients on tamoxifen, and gained on average 0.11 
QALYs per patient. This corresponds to an incremental cost of approximately SEK 
145,000 per QALY gained. CONCLUSIONS: This updated cost-effectiveness analysis 
of the ATAC trial is conservative, neither is any assumption made of an accrued sur-
vival beneﬁt due to a signiﬁcantly lower recurrence rate, nor does the analysis consider 
the potential reduction of costs associated with anastrozole patent expiry. Neverthe-
less, the study demonstrates that up-front anastrozole treatment for ﬁve years is a 
cost-effective option compared to ﬁve years tamoxifen treatment in the lifetime per-
spective for hormone receptor-positive patients.
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OBJECTIVES: The Brazilian guideline for the treatment of CML is not clear whether 
to increase imatinib dosage or switch to dasatinib for imatinib-resistant patients. The 
aim of this study was to evaluate the value of dasatinib versus imatinib 400 mg for 
treatment of imatinib-resistant CML patients (dasatinib 100 mg vs. imatinib 600 mg 
for CP and dasatinib 140 mg vs. imatinib 800 mg for AP and BP), from the Brazilian 
